TNFRSF18 and neoplasm: GITR on regulatory T cells has recently been described as a target for improved anti-tumour responses in liver cancer43 and a combined treatment consisting of anti-PD-1 and anti-GITR mAbs gave rise to anti-tumour immunity in mice by enhancing CD8+ effector T-cell functions44.